[MIK HOT SPOT_KHIDI] Genome & Company on its establishment, series C investment

137 Aufrufe

Danke für die Bewertung! Teile es mit Deinen Freunden!

Danke für Deine Bewertung!

Published May 22, 2020

Now Opening exhibition ! : http://madeinkorea.aving.net/

Genome & Company was listed in KONEX in just three years and attracted Series C investment in just five years of business. It has even signed contracts to cooperate in clinical trials and supply with a global pharmaceutical company, growing into one of the companies to receive the most attention among all biotech companies in Korea. Even in the faltering bio and pharmaceutical markets due to the COVID-19 pandemic, Genome & Company is keeping its position as the first place in the aggregate value of KONEX (275.8 billion won as of May 4).

In the beginning of the business, Genome & Company introduced the unfamiliar field of microbiome to the investors and had difficulties in attracting the investment. However, the market prospects for microbiome-based anticancer drugs and the R&D capabilities of Genome & Company were highly recognized by investors, and successfully attracted investments of Series A in 2016, Series B in 2018, and Series C in 2019.

Based on the successful investment attraction, Genome & Company signed a contract for cooperating in the clinical trial for the concomitant use of Bavencio (PD-L1 inhibitor) from Germany's Merck/Pfizer and microbiome treatment drug (GEN-001) from this company and the supply of it, and it was IND approved from US FDA in this April for conducting concomitant clinical trial. Not only that, in December last year, Genome & Company made an achievement of successfully signing the contract with LG Chem for the exclusive development and commercialization rights for GEN-001 in Korea and the East Asian region. Genome & Company is the first company in Korea to cooperate for concomitant clinical trial with Germany's Merck/Pfizer among microbiome R&D companies, and technology transfer to LG Chem is the first technology transfer of microbiome anticancer drugs in the world.

Such achievements have been made from the investment of the top-level human resources in business and clinical trial development for commercialization of research results, preparing the system that has capabilities in the areas of research/development/commercialization. Genome & Company hired specialists in clinical trial cooperation, global new drug development, and business development with multinational pharmaceutical companies like Hanmi Pharm and Celltrion, and they contributed greatly in achieving such successful business performances.

more information : http://us.aving.net/news/view.php?articleId=1571595&mn_name=

another article : https://url.kr/8ZCF12

AVING NEWS Official : http://us.aving.net/

AVING Yutube : https://www.youtube.com/user/avingusa...

Facebook : https://www.facebook.com/madeinkorea.tv/

Kategorien: Corona Virus aktuelle Videos

Kommentare deaktiviert.

Anmelden

[MIK HOT SPOT_KHIDI] Genome & Company on its establishment, series C investment

Als nächstes